Advice

Following a full submission

fondaparinux sodium (Arixtra®) is accepted for use within NHS Scotland for the treatment of ST segment elevation myocardial infarction (STEMI) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.

Fondaparinux significantly reduced mortality and reinfarction during the 30 days following onset of symptoms compared to placebo and was not associated with an increased risk of bleeding.

Download detailed advice55KB (PDF)

Download

Medicine details

Medicine name:
fondiparinux sodium (Arixtra)
SMC ID:
439/08
Indication:
Treatment of ST segment elevation myocardial infarction (STEMI) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.
Pharmaceutical company
GlaxoSmithKline UK Ltd
BNF chapter
Cardiovascular system
Submission type
Full
Status
Accepted
Date advice published
11 February 2008